No quarterly revenue total was found in GREENWICH LIFESCIENCES, INC.'s SEC filings.
Greenwich Lifesciences, Inc. (GLSI) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-3.95M
-5.3% vs year-ago quarter
Operating cash flow
$-1.94M
+13.1% vs year-ago quarter
Free cash flow
—
EPS
$-0.27
+3.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
14.68M
+7.7% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GLSI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Stafford, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1799788
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.0M | -$5.7M | -$7.9M | -$4.2M | -$3.8M |
| Net income | -$3.9M | -$5.7M | -$9.2M | -$3.7M | -$3.7M |
| Diluted EPS | -$0.27 | -$0.39 | -$0.66 | -$0.27 | -$0.28 |
| Operating cash flow | -$1.9M | -$4.7M | -$3.2M | -$2.7M | -$2.2M |
| Total assets | $8.9M | $10.5M | $6.2M | $3.8M | $3.1M |
| Total liabilities | $5.8M | $5.2M | $5.8M | $2.0M | $2.5M |
| Stockholders' equity | $3.1M | $5.3M | $353,217 | $2.2M | $604,302 |
| Cash and investments | $8.9M | $10.5M | $6.2M | $3.8M | $3.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 26, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | Jun 4, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Jun 1, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Dec 18, 2025 | Dec 18, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
All 279 Greenwich Lifesciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.